E VistaGen Therapeutics: Interesting Prospects


I believe that VistaGen is a company that should be on investors' radar. The next few years have a few major inflection points with data that could push the company to a higher valuation. The best part about the company is that it is using a different approach to treating MDD patients, unlike current antidepressants. Most of the current antidepressants target are SSRIs, or Selective serotonin reuptake inhibitors. They may have some efficacy for MDD patients but their side effects are pretty harsh. Vistagen’s AV-101 provides a major breakthrough in how MDD patients and other neurological disorders can be treated.

1 2 3 4
View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Paul B 3 years ago Member's comment

When I say I was in a different place that was when the drug was intravenous but until Wednesday very good. Regards Paul

Ayelet Wolf 3 years ago Member's comment

Thanks for sharing but I'm not clear what your point is Paul.

Paul B 3 years ago Member's comment

I suffer from MDD and was admitted to a psychiatric hospital.There are two hospitals in the UK and they are testing ketamine. One is Oxford and the other One is Northampton.The Dr ask me if I would be willing to take part in the test and when you suffered with depression for many years you would do anything to get out of the big black cloud that makes life unbearable.it was amazing it was like you were in a different place,so relaxing.The trials were every Friday you would document everyday on your computer.For me it was very effective but I noted it would last until Wednesday obviously this is a trial and as time when by they would now what dose you would require.But unfortunately I was taken of the test because I was on a very strong opioid and obviously they were testing a new drug and could not take any chances as it did not have a license. Regards Paul

Derek Snyder 3 years ago Member's comment

Your argument for acquisition sounds convincing, but I wonder if there have been any such overtures. Know if that's the case? Which companies would be the most likely to target #Vistagen? $VTGN.

David M. Green 3 years ago Member's comment

Looks promising. Sounds like $VTGN should be getting more love from investors.

Bill Johnson 3 years ago Member's comment

Definitely sounds like some interesting prospects indeed! $VTGN

Alexis Renault 3 years ago Member's comment

Thanks Terry Chrisomalis, can you explain what a "first-line, second-line, and third-line of treatment" is?

Terry Chrisomalis 3 years ago Author's comment

That is taking one SSRI drug for 4-8 weeks then it not working, then taking another SSRI drug for 4-8 weeks and it not working etc. Then eventually following up with adding atypical antipsychotics

Alexis Renault 3 years ago Member's comment

Thanks Terry! Will take a closer look at $VTGN.